Cancer Guidelines Database

Access quality cancer guidelines from a single Canadian source

We've listed 39 guidelines under your selection of "Location". The most recent guidelines are first.

Evidence Based Recommendations for the Assessment and Management of Radiation-Induced Skin Toxicities in Breast Cancer: Part 5. Management of Long-Term Effects

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Manitoba
This clinical practice guideline if part of a series of guidelines for adults with breast cancer who are experiencing radiation-induced skin toxicities. The guideline focuses on the management of long term effects, and provides recommendations on 1 month post-treatment and late reactions to promote cleanliness, treat the wound, prevent infections, protect from trauma and the environment, promote skin health and maintain skin flexibility.

Evidence Based Recommendations for the Assessment and Management of Radiation-Induced Skin Toxicities in Breast Cancer: Part 4. Management of Acute Radiation-Induced Skin Toxicities

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Manitoba
This clinical practice guideline if part of a series of guidelines for adults with breast cancer who are experiencing radiation-induced skin toxicities. The guideline focuses on the clinical assessment and management of these patients. Outcomes of interest include improved care delivery and quality of life, enhanced treatment compliance, as well as minimized patient burden regarding dressings (i.e. cost, frequency/difficulty of dressing changes).

Evidence Based Recommendations for the Assessment and Management of Radiation-Induced Skin Toxicities in Breast Cancer: Part 3. Skin Health Promotion: Health Promotion Interventions

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Manitoba
This clinical practice guideline if part of a series of guidelines for adults with breast cancer who are experiencing radiation-induced skin toxicities. The guideline provides recommendations regarding interventions aimed at the promotion of skin health. Specific topics discussed include the promotion of skin hygiene, promotion of comfort, preventing infections, protection from trauma, and protection from the environment.

Recommendations for Filgrastim Use in Adults by Disease Site

Year: 2018
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for adult oncology patients with neutropenia. The guideline examines the appropriate prescribing of filgrastim for these patients. Indications for which filgrastim should be used are discussed by disease site group. Disease site groups considered include breast, central nervous system, gastrointestinal, gynecologic, genitourinary, hematologic, and thoracic, amongst others.

Evidence Based Recommendations for the Assessment and Management of Radiation-Induced Skin Toxicities in Breast Cancer: Part 2. Skin Assessment for Breast Cancer Patients Receiving Radiation

Year: 2018
AGREE II score: Available
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for adults with breast cancer. The guideline provides recommendations on the assessment and management of radiation-induced skin toxicities in these patients. Outcomes of interest include quality of life, treatment compliance, and minimized patient burden regarding dressings (e.g. cost, frequency, and difficulty of dressing changes).

Provincial Consensus Recommendations for Adjuvant Systemic Therapy for Breast Cancer

Year: 2017
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for patients with breast cancer. The guideline examines common approaches for the treatment of breast cancer with adjuvant systemic therapy. A specific topic discussed is the use of adjuvant therapy for HER2 positive breast cancer, with recommendations for both oncologists and pathologists.

Consensus Recommendations for Management of Malignant Melanoma

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the management of malignant melanoma. Topics of interest include acceptable time intervals from referral to surgical management, which patients should be candidates for sentinel lymph node biopsy, and acceptable surgical margins.

Recommendations for Filgrastim Use in Adults by Disease Site

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline to guide appropriate prescribing of filgrastim in adults. The guidelines looks at a variety of disease sites and is intended as a guide to facilitate a shared approach to the appropriate use of filgrastim. In order provide clarity surrounding the indications in which filgrastim should be used, the recommendations are presented by disease site.

Consensus Recommendations for Management of Malignant Melanoma

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the clinical management of malignant melanoma with the aim of improving the standard of care received by this patient population. The guideline provides recommendations on referral to surgeons and associated wait times, procedures (e.g., biopsy), tumour markers, and adjuvant therapies.

Consensus Recommendations for the Management of Chronic Lymphocytic Leukemia: Primary Care Guideline

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with chronic lymphocytic leukemia (CLL), monoclonal B cell lymphocytosis (MBL) and small lymphocytic lymphoma (SLL). The guideline examines clinical assessment, staging, and treatment including supportive therapy and potential complications. Outcomes of interest include long-term remission, increases in secondary malignancies, and disease progression.

Consensus Recommendations for the Routine Use of Positron Emission Tomography (PET) Scan Imaging for Lymphoma in Manitoba

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with lymphoma, including small lymphocytic leukemia (SLL)/chronic lymphocytic leukemia (CLL), Waldenstroms, marginal zone lymphoma, and cutaneous lymphoma. The guideline examine the use of PET/CT, primarily for staging and response assessment. Outcomes of interest include survival, quality of life, and appropriate use.

Second-Line Treatment of Metastatic Non-Small Cell Lung Cancer with Pemetrexed

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the treatment of metastatic non-small cell lung cancer. The guideline facilitates the safe and effective clinical use of pemetrexed for this population. The treatment intent is non-curative and meant to prolong overall survival and progression-free survival, as well as improve quality of life.

Evidence-Based Recommendations for the Management of Potentially Curable Esophageal Carcinoma

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for adult patients with potentially curable esophageal carcinoma. The guideline examines diagnosis with FDG-PET/CT, staging, and treatment options including chemoradiotherapy and brachytherapy. Outcomes of interest include staging accuracy and treatment response.

Treatment of BRAF V600 Mutated Advanced Melanoma with Trametinib

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the treatment of mutated advanced melanoma. The guideline facilitates the safe and effective clinical use of the systemic therapy trametinib. The treatment intent is to improve quality of life and decrease symptom burden.

Second-Line Treatment of Metastatic Melanoma with Ipilimumab

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the second line treatment of metastatic melanoma. The guideline facilitates the safe and effective clinical use of the systemic therapy ipilimumab. The treatment intent of this guideline is non-curative and to improve overall survival, as well as progression free survival.

First-Line Treatment of BRAF V600 Mutated Metastatic Melanoma with Vemurafenib

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the treatment of mutated metastatic melanoma. The guideline facilitates the safe and effective clinical use of the systemic therapy vemurafenib. The treatment intent of this guideline is non-curative and to improve overall survival, as well as progression free survival.

Treatment of Relapsed/Refractory Hodgkin Lymphoma with Brentuximab Vedotin

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with relapsed/refractory Hodgkin's lymphoma. The guideline examines treatment with brentuximab vedotin. Outcomes of interest include progression-free and overall survival.

Treatment of Chronic Lymphocytic Leukemia With Pentostatin, Cyclophosphamide and Rituximab

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with chronic lymphocytic leukemia. The guideline examines treatment with pentostatin, cyclophosphamide and rituximab (PCR) for patients who have undergone prior treatments including allogeneic stem cell transplant and fludarabine-based therapy. Outcomes of interest include minimized myelosupression and infection risk.

Treatment of Relapsed/Refractory Anaplastic Large Cell Lymphoma with Brentuximab Vedotin

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the treatment of relapsed/refractory anaplastic large cell lymphoma. The guideline facilitates the safe and effective clinical use of brentuximab vedotin. The treatment intent is non-curative and to improve progression-free survival and overall survival.

Provincial Consensus Recommendations on the Evaluation, Diagnosis and Management of a Suspicious Lateral Neck Mass

Year: 2015
AGREE II score: Available
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the evaluation, diagnosis and management of a suspicious lateral neck mass in adults. Use of history and physical exam, X-ray, CT scan, and fine needle aspiration biopsy (FNAB) are discussed along with urgency of referral depending on results. Additionally, the guideline addresses the diagnosis or suspicion of lymphoma, as well as appropriate use of open biopsy.

First- or Second-Line Treatment of Metastatic or Locally Advanced Uterine Leiomyosarcoma with Fixed-Dose Rate Gemcitabine and Docetaxel

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the systemic first- or second-line treatment of metastatic or locally advanced uterine leiomyosarcoma. The guide facilitates the safe and effective clinical use of fixed-dose rate gemcitabine and docetaxel. Treatment outcomes are non-curative and look to prolong progression-free survival and overall survival.

Adjuvant Treatment of Completely Resected Stages I-IV Uterine Leiomyosarcoma with Fixed-Dose Rate Gemcitabine and Docetaxel

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the adjuvant treatment of completely resected stages I-IV uterine leiomyosarcoma. The guideline is intended to guide the safe and effective clinical use of fixed-dose rates of gemcitabine and docetaxel. Treatment outcomes are potentially curative and to improve progression-free survival, as well as overall survival.

Dose-Dense Paclitaxel Combined With Carboplatin for Advanced/Metastatic Ovarian Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a systemic therapy summary for the use of dose-dense paclitaxel combined with carboplatintherapy to treat adults with stage 2-4 ovarian/fallopian/peritoneal cancer (with curative intent or to prolong survival). Treatment regimen, drug dose, and administration are reviewed, along with pre-medications, supportive care, suggested outpatient prescriptions, and recommendations for clinical monitoring and follow-up care. The guideline also addresses adverse events, precautions, dose modifications, and drug interactions.

Bevacizumab, Paclitaxel and Carboplatin for Metastatic Cervical Carcinoma

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a systemic therapy summary for the use of bevacizumab, paclitaxel and carboplatin as therapy options for adults with recurrent, persistent or metastatic cervical cancer. Treatment regimen, drug dose, and administration are reviewed, and recommendations provided for clinical monitoring and follow-up care. The guideline also addresses adverse events, precautions, dose modifications, and drug interactions.

Post-Docetaxel Treatment of Metastatic Castrate‐Resistant Prostate Cancer With Abiraterone and Prednisone

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for patients with metastatic castrate-resistant prostate cancer who have been previously treated with docetaxel. The guideline provides recommendations on treatment with abiraterone and prednisone including treatment regimen and recommendations for pre-medications, supportive care, clinical monitoring and follow-up care. Additionally, adverse effects, precautions, dose modifications, and drug interactions are discussed.

First-Line Treatment of Advanced Renal Cell Carcinoma With Temsirolimus

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for patients with advanced or metastatic renal cell carcinoma (both clear cell and non-clear cell histology) with poor prognosis. The guideline provides recommendations for treatment with temsirolimus, including treatment regimen and recommendations for clinical monitoring and follow-up care. Pre-medication and supportive care is discussed along with adverse events, precautions, and drug interactions.

First-Line Treatment of Advanced Renal Cell Carcinoma With Oral Sunitinib

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This clinical practice guideline discusses the use of oral sunitinib as first-line treatment in patients with advanced/metastatic renal cell carcinoma of clear-cell histology who have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2 and who are of low to intermediate risk as defined by Memorial Sloan Kettering Cancer Centre (MSKCC) risk status. The guideline provides a treatment regimen and recommendations for clinical monitoring and follow-up care. Clinical toxicity assessment is discussed along with common or clinically important adverse events and drug interactions.

Provincial Consensus on Diagnostic and Treatment Recommendations for the Management of Rectal Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This clinical practice guideline provides recommendations on the diagnosis and treatment of rectal cancer in adult patients. Imaging procedures for staging are discussed with comparisons made between ultrasound, MRI, and CT scan. Treatment options include neoadjuvant and adjuvant chemotherapy as well as rectal cancer surgery, specifically total mesorectal excision (TME). Surgical management of recurrent rectal adenocarcinoma is also discussed.

Second-Line Treatment of Advanced Pancreatic Cancer with Oxaliplatin, Fluorouracil and Leucovorin (OFF Regimen)

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with advanced or metastatic pancreatic cancer. The guideline examines the use of oxaliplatin, fluorouracil and leucovorin in patients who had received, or were intolerant to, gemcitabine-based therapy. Outcomes of interest include progression-free and overall survival.

First-Line Treatment of HER2/neu Positive Locally Advanced, Recurrent or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction with Trastuzumab

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with human epidermal growth factor receptor 2 (HER2)/neu positive locally advanced, recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction. The guideline examines the use of trastuzumab in conjunction with cisplatin and fluorouracil or capecitabine as a first-line treatment. Outcomes of interest include progression-free and overall survival.

First-Line Treatment of Metastatic Pancreatic Adenocarcinoma with FOLFIRINOX

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with metastatic pancreatic adenocarcinoma. The guideline examines the use of folfirinox - a combination of fluorouracil, oxaliplatin, leucovorin and irinotecan - as a first-line treatment. Outcomes of interest include progression-free and overall survival.

Third-Line Treatment of Stage IV or Advanced, Unresectable Colorectal Carcinoma with Cetuximab

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with stage IV or advanced, unresectable colorectal carcinoma. The guideline examines the use of cetuximab as a third-line therapy once other therapies, including fluoropyrimidines, oxaliplatin, or irinotecan, had been tried or when patients are intolerant to other options. Outcomes of interest include progression-free and overall survival.

Smoking Cessation in Oncology Care

Year: 2015
AGREE II score: Available
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with any type of cancer. The guideline examines the benefits of smoking cessation, and education for quitting once a patient has been diagnosed with cancer. Outcomes of interest include quality of life and treatment-related toxicity.

Arsenic Trioxide for Acute Promyelocytic Leukemia

Year: 2014
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the treatment of acute promyelocytic leukemia with arsenic trioxide. The treatment is intended to be curative and to decrease regimen toxicity. Developers noted that acute promyelocytic leukemia is a rare subtype of acute leukemia (2.5 new cases in Manitoba per year in the last 10 years).

First-Line Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) with Fludarabine, Cyclophosphamide, and Rituximab (FCR Regimen)

Year: 2013
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with newly diagnosed chronic lymphocytic leukemia (CLL). The guideline examines first-line treatment of CLL with fludarabine, cyclophosphamide, and rituximab (FCR Regimen). Outcomes of interest include progression-free and overall survival.

Primary Curative Therapy for Head and Neck Squamous Cell Carcinoma with Cetuximab in Combination with Radiation

Year: 2013
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline that facilitates the safe and effective clinical use of cetuximab in combination with radiation as the primary curative therapy for head and neck squamous cell carcinoma in the adult population. This guidelines specifically considers patients with contraindications to platinum based chemotherapy and/or those over the age of 70.

First-Line Palliative Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Cetuximab, Platinum, and 5 FU

Year: 2013
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This practice guideline reviews first-line palliative treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma. The use of cisplatin with 5-fluorouracil with or without cetuximab is compared, and recommendations are provided for treatment regimen, laboratory tests (baseline, weekly, and per cycle), clinical considerations, and assessment of treatment response. Dose modifications are also discussed.

Guidelines for Breast, Cervical and Colorectal Cancer Screening

Year: 2013
AGREE II score: Unavailable
Developer organization: CancerCare Manitoba
This guideline provides screening recommendations for breast, cervical, and colorectal cancer, based on age and risk factors. Management of test results including mammography, cytology, occult blood test (FOBT) and colonoscopy are discussed, and potential benefits and harms are reviewed. Other testing procedures include ultrasound, stereotactic core biopsy, colposcopy, endocervical curettage, endometrial biopsy, flexible sigmoidoscopy, and colonoscopy.